Menu
Post-Trial Access (PTA) is more than an ethical obligation—it’s a strategic opportunity to demonstrate patient commitment, extend treatment benefit, and
Currently there are 6,000 recognised rare diseases, affecting over 300 million people globally. Despite these staggering numbers, only 5% of
Clinical trials are by design, a scientific experiment, which require highly selective populations in a controlled setting, and with often
Real-world evidence (RWE) is increasingly being used within the regulatory and reimbursement process. RWE studies allow for a clearer understanding
To find out more about the Cisiv technology and how we can help you with your study.